[HTML][HTML] Gefitinib plus celecoxib in chemotherapy-naive patients with stage IIIB/IV non-small cell lung cancer: a phase II study from the Hoosier Oncology Group
A Agarwala, W Fisher, D Bruetman, J McClean… - Journal of Thoracic …, 2008 - Elsevier
Background Gefitinib, an inhibitor of the epidermal growth factor receptor (EGFR) pathway,
has single agent activity in non-small cell lung cancer (NSCLC). Preclinical studies …
has single agent activity in non-small cell lung cancer (NSCLC). Preclinical studies …
[HTML][HTML] Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in …
SM Gadgeel, JC Ruckdeschel, EI Heath… - Journal of Thoracic …, 2007 - Elsevier
Background: Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, has
demonstrated a response rate of 9%–18% in relapsed non-small cell lung cancer (NSCLC) …
demonstrated a response rate of 9%–18% in relapsed non-small cell lung cancer (NSCLC) …
[PDF][PDF] Combination therapy with gefitinib and rofecoxib in patients with platinum-pretreated relapsed non–small-cell lung cancer
KJ O'Byrne, S Danson, D Dunlop… - Journal of clinical …, 2007 - researchgate.net
Purpose In non–small-cell lung cancer (NSCLC), the epidermal growth factor receptor
(EGFR) and cyclooxygenase-2 (COX-2) play major roles in tumorigenesis. This phase I/II …
(EGFR) and cyclooxygenase-2 (COX-2) play major roles in tumorigenesis. This phase I/II …
[引用][C] O-113 Clinical evaluation of gefitinib (Iressa, ZD1839) in combination with rofecoxib in cisplatin pre-treated relapsed non-small cell lung cancer
KJ O'Byrne, L Clarke, D Dunlop, M Ranson, S Danson… - Lung Cancer, 2003 - infona.pl
O-113 Clinical evaluation of gefitinib (Iressa, ZD1839) in combination with rofecoxib in
cisplatin pre-treated relapsed non-small cell lung cancer × Close The Infona portal uses …
cisplatin pre-treated relapsed non-small cell lung cancer × Close The Infona portal uses …
Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.
J Ahn, S Kim, M Ahn, J Lee, J Uhm, J Sun… - Journal of Clinical …, 2010 - ascopubs.org
7551 Background: Gefitinib and erlotinib are potent inhibitors of the epidermal growth factor
receptor tyrosine kinase (EGFR TK), with single agent antitumor activity. In this randomized …
receptor tyrosine kinase (EGFR TK), with single agent antitumor activity. In this randomized …
Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839,'Iressa') on an expanded access study
PA Jänne, S Gurubhagavatula, BY Yeap, J Lucca… - Lung cancer, 2004 - Elsevier
Purpose: To investigate the anti-tumor activity and toxicity of the epidermal growth factor
receptor (EGFR) inhibitor gefitinib (ZD1839 or Iressa™; AstraZeneca Pharmaceuticals …
receptor (EGFR) inhibitor gefitinib (ZD1839 or Iressa™; AstraZeneca Pharmaceuticals …
Randomized phase 2 trial of erlotinib in combination with high‐dose celecoxib or placebo in patients with advanced non‐small cell lung cancer
KL Reckamp, M Koczywas, MC Cristea, JE Dowell… - Cancer, 2015 - Wiley Online Library
BACKGROUND Cyclooxygenase 2 (COX‐2)‐dependent signaling represents a potential
mechanism of resistance to therapy with epidermal growth factor receptor (EGFR) tyrosine …
mechanism of resistance to therapy with epidermal growth factor receptor (EGFR) tyrosine …
A phase II study of first-line single agent of gefitinib in patients (pts) with stage IV non-small cell lung cancer (NSCLC)
R Suzuki, Y Hasegawa, K Baba, H Saka… - Journal of Clinical …, 2005 - ascopubs.org
7082 Background: Gefitinib has shown modest activity in pts with recurrent NSCLC after
platinum-based chemotherapy. However, the activity of gefitinib as first-line chemotherapy …
platinum-based chemotherapy. However, the activity of gefitinib as first-line chemotherapy …
Gefitinib in combination with paclitaxel and carboplatin in advanced non–small-cell lung cancer: a phase III trial—INTACT 2
RS Herbst, G Giaccone, JH Schiller… - Journal of Clinical …, 2004 - ascopubs.org
Purpose Preclinical studies indicate that gefitinib (Iressa, ZD1839; AstraZeneca, Wilmington,
DE), an orally active epidermal growth factor receptor tyrosine kinase inhibitor, may enhance …
DE), an orally active epidermal growth factor receptor tyrosine kinase inhibitor, may enhance …
Gefitinib in patients with advanced non-small cell lung cancer (NSCLC): the expanded access protocol experience at the University of Pennsylvania
ML Veronese, K Algazy, L Bearn, B Eaby… - Cancer …, 2005 - Taylor & Francis
Gefitinib (Iressa; AstraZeneca Pharmaceuticals, Wilmington, DE) is an oral epidermal growth
factor receptor tyrosine kinase inhibitor (EGFR-TKI) with favorable toxicity and antitumor …
factor receptor tyrosine kinase inhibitor (EGFR-TKI) with favorable toxicity and antitumor …